Literature DB >> 11834448

Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat.

E Bojanowska1, B Stempniak.   

Abstract

To date, glucagon-like peptide 1(7-36) amide (tGLP-1) has been found to affect the neurohypophysial and cardiovascular functions in normotensive and normovolaemic rats. The aim of the present study was to investigate possible effects of tGLP-1 on the mean arterial blood pressure and the release of vasopressin and oxytocin under conditions of blood volume depletion in the rat. In the first series of experiments, the animals were injected i.p. with either 0.15 M saline or 30% polyethylene glycol (PEG). PEG caused an 18% reduction of blood volume 1 h after injection. No significant changes in the mean arterial blood pressure were found in either normo- or hypovolaemic rats during the experiment. tGLP-1 injected i.c.v. at a dose of 1 microg/5 microl 1 h after the i.p. injection increased similarly the arterial blood pressure in normo- and hypovolaemic rats. The plasma vasopressin/oxytocin concentrations were markedly elevated in hypovolaemic animals and tGLP-1 further augmented the release of both hormones. In the second study, hypovolaemia was induced by double blood withdrawal. The haemorrhage resulted in a marked decrease of the mean arterial blood pressure and in the elevated plasma vasopressin/oxytocin concentrations. tGLP-1 injected immediately after the second blood withdrawal increased the arterial blood pressure. In parallel, tGLP-1 enhanced significantly vasopressin and oxytocin secretion when compared with haemorrhaged, saline-injected rats. The results of this study indicate that tGLP-1 may affect the arterial blood pressure and the secretion of neurohypophysial hormones under pathological conditions brought about by blood volume depletion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834448     DOI: 10.1677/joe.0.1720303

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.

Authors:  Masamitsu Iwasa; Yoshihisa Yamada; Hiroyuki Kobayashi; Shinji Yasuda; Itta Kawamura; Shohei Sumi; Takeru Shiraki; Takahiko Yamaki; Hiroaki Ushikoshi; Arihiro Hattori; Takuma Aoyama; Kazuhiko Nishigaki; Genzou Takemura; Hisayoshi Fujiwara; Shinya Minatoguchi
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett; D J Baker
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

3.  Investigation of the haemodynamic effects of exenatide in healthy male subjects.

Authors:  Buddhike Mendis; Elizabeth Simpson; Ian MacDonald; Peter Mansell
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 4.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

5.  Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

Review 6.  Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure.

Authors:  Jian Yang; Pedro A Jose; Chunyu Zeng
Journal:  J Am Heart Assoc       Date:  2017-03-06       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.